Cargando…

Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer

Background: Adjuvant radiotherapy (RT) is an integral component of a multidisciplinary treatment strategy for early-stage breast cancer. It significantly reduces the incidence of loco-regional recurrence but also of distant events. Distant events are due to tumor cells disseminated from the primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Mäurer, Matthias, Schott, Dorothea, Pizon, Monika, Drozdz, Sonia, Wendt, Thomas, Wittig, Andrea, Pachmann, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857667/
https://www.ncbi.nlm.nih.gov/pubmed/36661670
http://dx.doi.org/10.3390/curroncol30010021
_version_ 1784873920322600960
author Mäurer, Matthias
Schott, Dorothea
Pizon, Monika
Drozdz, Sonia
Wendt, Thomas
Wittig, Andrea
Pachmann, Katharina
author_facet Mäurer, Matthias
Schott, Dorothea
Pizon, Monika
Drozdz, Sonia
Wendt, Thomas
Wittig, Andrea
Pachmann, Katharina
author_sort Mäurer, Matthias
collection PubMed
description Background: Adjuvant radiotherapy (RT) is an integral component of a multidisciplinary treatment strategy for early-stage breast cancer. It significantly reduces the incidence of loco-regional recurrence but also of distant events. Distant events are due to tumor cells disseminated from the primary tumor into lymphatic fluid or blood, circulating epithelial tumor cells (CETC/CTC), which can reach distant tissues and regrow into metastases. The purpose of this study is to determine changes in the number of CETC/CTC in the course of adjuvant RT, and to evaluate whether they are correlated to local recurrence and distant metastases in breast cancer patients. Methods: Blood from 165 patients irradiated between 2002 and 2012 was analyzed 0–6 weeks prior to and 0–6 weeks after RT using the maintrac(®) method, and patients were followed over a median period of 8.97 (1.16–19.09) years. Results: Patients with an increase in CETC/CTC numbers over the course of adjuvant RT had a significantly worse disease-free survival (p = 0.004) than patients with stable or decreasing CETC/CTC numbers. CETC/CTC behavior was the most important factor in predicting subsequent relapse-free survival. In particular, patients who had received neoadjuvant chemotherapy were disproportionately more likely to develop metastases when cell counts increased over the course of RT (p = 0.003; hazard ratio 4.886). Conclusions: Using the maintrac(®) method, CETC/CTC were detected in almost all breast cancer patients after surgery. The increase in CETC/CTC numbers over the course of RT represents a potential predictive biomarker to judge relative risk/benefit in patients with early breast cancer. The results of this study highlight the need for prospective clinical trials on CETC/CTC status as a predictive criterion and for individualization of treatment. Clinical Trial registration: The trial is registered (2 May 2019) at trials.gov under NCT03935802.
format Online
Article
Text
id pubmed-9857667
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98576672023-01-21 Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer Mäurer, Matthias Schott, Dorothea Pizon, Monika Drozdz, Sonia Wendt, Thomas Wittig, Andrea Pachmann, Katharina Curr Oncol Article Background: Adjuvant radiotherapy (RT) is an integral component of a multidisciplinary treatment strategy for early-stage breast cancer. It significantly reduces the incidence of loco-regional recurrence but also of distant events. Distant events are due to tumor cells disseminated from the primary tumor into lymphatic fluid or blood, circulating epithelial tumor cells (CETC/CTC), which can reach distant tissues and regrow into metastases. The purpose of this study is to determine changes in the number of CETC/CTC in the course of adjuvant RT, and to evaluate whether they are correlated to local recurrence and distant metastases in breast cancer patients. Methods: Blood from 165 patients irradiated between 2002 and 2012 was analyzed 0–6 weeks prior to and 0–6 weeks after RT using the maintrac(®) method, and patients were followed over a median period of 8.97 (1.16–19.09) years. Results: Patients with an increase in CETC/CTC numbers over the course of adjuvant RT had a significantly worse disease-free survival (p = 0.004) than patients with stable or decreasing CETC/CTC numbers. CETC/CTC behavior was the most important factor in predicting subsequent relapse-free survival. In particular, patients who had received neoadjuvant chemotherapy were disproportionately more likely to develop metastases when cell counts increased over the course of RT (p = 0.003; hazard ratio 4.886). Conclusions: Using the maintrac(®) method, CETC/CTC were detected in almost all breast cancer patients after surgery. The increase in CETC/CTC numbers over the course of RT represents a potential predictive biomarker to judge relative risk/benefit in patients with early breast cancer. The results of this study highlight the need for prospective clinical trials on CETC/CTC status as a predictive criterion and for individualization of treatment. Clinical Trial registration: The trial is registered (2 May 2019) at trials.gov under NCT03935802. MDPI 2022-12-24 /pmc/articles/PMC9857667/ /pubmed/36661670 http://dx.doi.org/10.3390/curroncol30010021 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mäurer, Matthias
Schott, Dorothea
Pizon, Monika
Drozdz, Sonia
Wendt, Thomas
Wittig, Andrea
Pachmann, Katharina
Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer
title Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer
title_full Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer
title_fullStr Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer
title_full_unstemmed Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer
title_short Increased Circulating Epithelial Tumor Cells (CETC/CTC) over the Course of Adjuvant Radiotherapy Is a Predictor of Less Favorable Outcome in Patients with Early-Stage Breast Cancer
title_sort increased circulating epithelial tumor cells (cetc/ctc) over the course of adjuvant radiotherapy is a predictor of less favorable outcome in patients with early-stage breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857667/
https://www.ncbi.nlm.nih.gov/pubmed/36661670
http://dx.doi.org/10.3390/curroncol30010021
work_keys_str_mv AT maurermatthias increasedcirculatingepithelialtumorcellscetcctcoverthecourseofadjuvantradiotherapyisapredictoroflessfavorableoutcomeinpatientswithearlystagebreastcancer
AT schottdorothea increasedcirculatingepithelialtumorcellscetcctcoverthecourseofadjuvantradiotherapyisapredictoroflessfavorableoutcomeinpatientswithearlystagebreastcancer
AT pizonmonika increasedcirculatingepithelialtumorcellscetcctcoverthecourseofadjuvantradiotherapyisapredictoroflessfavorableoutcomeinpatientswithearlystagebreastcancer
AT drozdzsonia increasedcirculatingepithelialtumorcellscetcctcoverthecourseofadjuvantradiotherapyisapredictoroflessfavorableoutcomeinpatientswithearlystagebreastcancer
AT wendtthomas increasedcirculatingepithelialtumorcellscetcctcoverthecourseofadjuvantradiotherapyisapredictoroflessfavorableoutcomeinpatientswithearlystagebreastcancer
AT wittigandrea increasedcirculatingepithelialtumorcellscetcctcoverthecourseofadjuvantradiotherapyisapredictoroflessfavorableoutcomeinpatientswithearlystagebreastcancer
AT pachmannkatharina increasedcirculatingepithelialtumorcellscetcctcoverthecourseofadjuvantradiotherapyisapredictoroflessfavorableoutcomeinpatientswithearlystagebreastcancer